Managers / Q2 2022 · view latest →
FRAZIER MANAGEMENT LLC
CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200
Summary
Frazier Management LLC reported $1M in U.S.-listed holdings across 1 positions for Q2 2022.
The portfolio is heavily concentrated: Sierra Oncology alone accounts for 100.0% of reported value.
Compared with Q1 2022, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 100.0% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ALLENA PHARMACEUTICALS | SOLD OUT | −1.02M | 0 | −$236,000 | $0 |
| SIERRA ONCOLOGY INC | TRIMMED | −34.3K | 20.3K | −$635,000 | $1M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SIERRA ONCOLOGY INC | COM NEW | 100.00% | $1M | 20.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $0 | 1 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1M | 1 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | Under review | 2 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.3B | 43 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.2B | 41 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.1B | 34 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.2B | 35 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.3B | 35 | Feb 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.1B | 31 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.1B | 26 | Aug 4, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $882M | 25 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $596M | 20 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $320M | 19 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $390M | 18 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $415M | 17 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $388M | 17 | Feb 11, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.